Wednesday, November 13, 2024

November 2024 Meeting Agendas

 https://www.personalizedmedicineconference.org/schedule/


November 13 2024

An Evolving Landscape

8:00 a.m.

Registration and Breakfast

8:50 a.m.

President’s Message

SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition


LEARN MORE

9:00 a.m.

Amgen, Personalized Medicine, and the Future of the Pharmaceutical Industry

For nearly two decades, Amgen, a global leader in the pharmaceutical industry, has leaned into the development of innovative personalized medicines that promise big benefits for relatively small patient populations. Executive Vice President David Reese discusses the future of the company and the field.


MODERATOR | Clifton Leaf, former Editor-in-Chief, Fortune magazine


KEYNOTE SPEAKER | David Reese, M.D., Executive Vice President, Chief Technology Officer, Amgen


LEARN MORE

9:30 a.m.

Illumina’s Next Steps and the Future of Personalized Medicine

Illumina, a $23 billion genomic sequencing technology company, has broad-based ambitions for personalized medicine to transform health care across multiple fronts. CEO Jacob Thaysen reveals his vision for the future.


MODERATOR | Clifton Leaf, former Editor-in-Chief, Fortune magazine


KEYNOTE SPEAKER | Jacob Thaysen, Ph.D., CEO, Illumina


LEARN MORE

10:00 a.m.

Networking Break

10:45 a.m.

Investing in Diagnostics

Personalized medicine depends on a strong diagnostics industry, which faces an uncertain future. This panel examines the perspectives of investors and senior executives on the financial future of the industry.


MODERATOR | Michael D. Goldberg, Executive Chairman, DNAnexus, Chairman, CareDx


Brian Caveney, M.D., Chief Medical & Scientific Officer, Labcorp


Michael Pellini, M.D., General Partner, S32


Sam Raha, Chief Operating Officer, Myriad Genetics


Matthew Sykes, Managing Director, Life Sciences and Diagnostics Industry Investments, Goldman Sachs


LEARN MORE

11:30 a.m.

Presentation of the Annual Award for Leadership in Personalized Medicine

The Annual Award for Leadership in Personalized Medicine recognizes an individual whose contributions in science, business, and policy have helped advance the frontiers of the field.


PRESENTER | Brian Munroe, Founder, Board Member, Personalized Medicine Coalition


AWARDEE | Emily Kramer-Golinkoff, Co-Founder, Emily’s Entourage


LEARN MORE

12:00 p.m.

Lunch Break

12:30 p.m.

Sponsored Session/Room 217 | Transforming Standard-of-Care Imaging into Precision Diagnostics

MODERATOR | Ángel Alberich-Bayarri, Ph.D., Founder, CEO, Quibim (session sponsor)


Chiranjiv Singh, Vice President & General Manager, Pixel at Tempus AI


Okan Ekinci, M.D., Chief Medical Information Officer, Roche Information Solutions


Megan Nacar, Vice President of Commercial, DeciBio


1:00 p.m.

Three Decades as Executive, Caregiver, and Philanthropist: Christi Shaw Reflects

Christi Shaw has served as the CEO of a pioneering biopharmaceutical company, as a board member for several life sciences companies, and as a co-founder of the More Moments More Memories Foundation. She also spent a year as a full-time caregiver to her sister. Ms. Shaw reflects on three decades of service to the health care community.


MODERATOR | Kathy Bloomgarden, CEO, Ruder Finn


SPEAKER | Christi Shaw, former CEO, Kite Pharma


LEARN MORE

1:30 p.m.

Personalized Medicine: A Global Endeavor

All countries benefit from the advancement of personalized medicine. National leaders reflect on shared challenges and opportunities.


MODERATOR | Antonio Andreu, M.D., Ph.D., Scientific Director, European Infrastructure for Translational Medicine


Joshua C. Denny, M.D., CEO, All of Us Research Program, U.S. National Institutes of Health


Monika Frenzel, Ph.D., Research Funding and Support Leader, European Partnership for Personalised Medicine; International Coordinator, French National Research Agency


LEARN MORE

2:00 p.m.

Early Detection and the Future of Cancer Care

By detecting molecular cancer signals in the bloodstreams of seemingly healthy patients, a new generation of minimally invasive early cancer detection tests promises to put more patients on the path to personalized cancer treatment, sooner. What might this mean for the future of cancer care? Leading voices discuss.


MODERATOR | Felice Freyer, President, Association of Health Care Journalists


Christina Annunziata, M.D., Ph.D., Senior Vice President, Extramural Discovery Science, American Cancer Society


Tomasz Beer, M.D., Chief Medical Officer, Multi-Cancer Early Detection, Exact Sciences


Bruce Ratner, Author, Early Detection: Catching Cancer When It’s Curable


Sapna Syngal, M.D., M.P.H., Director of Strategic Planning for Prevention and Early Cancer Detection, Dana-Farber Cancer Institute


LEARN MORE

3:00 p.m.

Networking Break

3:45 p.m.

Pediatrics and Personalized Medicine

The era of personalized medicine has brought breakthrough advancements in areas like genomic sequencing and gene therapy. Will this reshape the futures of pediatric patients with rare genetic diseases? Leading voices discuss opportunities and challenges.


MODERATOR | Paul Billings, M.D., Ph.D., Board Member, Xzom


Lillian Garvin, Operations Lead, Center of Precision Medicine, Nicklaus Children’s Hospital


Mira Irons, M.D., Associate Chief, Genetics and Genomics, Boston Children’s Hospital


Julia Vitarello, Mila’s mom, Founder, CEO, Mila’s Miracle Foundation


LEARN MORE

4:30 p.m.

Visions for AI and the Future of Personalized Medicine

Artificial intelligence technologies can query the divergent effects of preventive and treatment interventions across a previously unimaginable range of data points. What might this mean for the future of personalized medicine? Leading voices share visions.


CHAIRPERSON | Joe Franklin, Ph.D., J.D., Special Counsel, Covington & Burling LLP


Ángel Alberich-Bayarri, Ph.D., Founder, CEO, Quibim


Okan Ekinci, M.D., Chief Medical Information Officer, Roche Information Solutions


John Ellithorpe, Ph.D., President, DNAnexus


Jonathan Kish, Ph.D., Head of Research Sciences, Flatiron Health


Kate Sasser, Ph.D., Chief Scientific Officer, Tempus


LEARN MORE

5:30 p.m.

Closing Remarks

SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition


6:00 p.m.

Signature Reception

Museum of Fine Arts

465 Huntington Avenue

Boston, MA 02115


NOVEMBER 14, 2024 PMC


A Systemic Response

8:00 a.m.

Registration and Breakfast

8:55 a.m.

Opening Remarks

SPEAKER | Lincoln Nadauld, M.D., Ph.D., President, CEO, Culmination Bio


9:00 a.m.

PhRMA’s Perspective on United States Public Policies and the Future of Personalized Medicine

As the Chief Medical Officer of the pharmaceutical industry’s leading trade association, Michael Ybarra, an emergency medicine physician, is helping industry executives shape and navigate shifting scientific, economic, and political landscapes in Washington and around the world. Dr. Ybarra shares the pharmaceutical industry’s point-of-view on the status and future of personalized medicine in light of recent public policy changes in the United States.


INTRODUCTION | Cynthia A. Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition


KEYNOTE SPEAKER | Michael Ybarra, M.D., Chief Medical Officer, PhRMA


LEARN MORE

9:30 a.m.

Precision Partnership: Point32Health/GRAIL Discuss Payer Coverage Pilot Program for Multi-Cancer Early Detection Testing

GRAIL and Point32Health are evaluating the impact of blood-based screening tests used to detect cancers before they cause symptoms in a real-world health plan setting. Partner executives reflect on the findings to date.


MODERATOR | Felice Freyer, President, Association of Health Care Journalists


Joshua Ofman, M.D., President, GRAIL


Kate Wallis, Vice President, Clinical Innovation, Point32Health


10:15 a.m.

Networking Break

11:00 a.m.

Clinical Adoption of Personalized Medicine: Opportunities and Challenges

For clinical care providers, personalized medicine may present opportunities to improve care for their patients and make better use of scarce resources by targeting treatments to those most likely to benefit from them. But spearheading the clinical adoption of personalized medicine is anything but easy. Representatives from leading clinical institutions reflect on opportunities and challenges.


MODERATOR | Susanne Munksted, Chief Precision Medicine Officer, Diaceutics


Justin Brueck, System Vice President, Innovation and Research, Endeavor Health


Manoja Lecamwasam, Ph.D., System Vice President, Intellectual Property, Strategic Life Sciences and Device Innovation, CommonSpirit Health


Apostolia M. Tsimberidou, M.D., Ph.D., Professor, Department of Investigational Therapeutics, The University of Texas MD Anderson Cancer Center


LEARN MORE

11:45 a.m.

Introducing a Clinical Adoption Roadmap for Precision Cancer Care

Daryl Pritchard, who serves as the Senior Vice President for Science Policy at the Personalized Medicine Coalition, introduces the Coalition’s new Roadmap for Addressing Clinical Practice Gaps in Precision Cancer Care.


SPEAKER | Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, Personalized Medicine Coalition


LEARN MORE

12:00 p.m.

Personalized Medicine: 20 Years Later

After the first sequencing of a human genome in 2003, officials from the U.S. National Institutes of Health introduced personalized medicine as a “newly created discipline” that promised to “make a profound difference to the health and well-being of all the people of this world.” Pioneering leaders reflect on the past, present, and future of this promise.


MODERATOR | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition


Mark Levin, Partner, Third Rock Ventures


Ralph Snyderman, M.D., Chancellor Emeritus, Duke University


Janet Woodcock, M.D., former Acting Commissioner, U.S. Food and Drug Administration


LEARN MORE

1:00 p.m.

Closing Remarks

SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition



###


FOCR

https://friendsofcancerresearch.org/event/friends-of-cancer-research-annual-meeting-2024/

Friends of Cancer Research (Friends) is proud to host our 17th Annual Meeting. This year’s annual meeting will explore three different topics that focus on approaches for streamlining trial designs and data collection to support efficient regulatory processes and decision-making. Topics presented at the 2024 Annual Meeting will address frequently encountered challenges that can impact the efficiency and conduct of clinical trials, and ultimately, the collection of evidence necessary to support new drug approvals. Please register above and stay tuned for additional updates. 


Draft Agenda


10:00 AM: Opening Remarks


10:05 AM: Morning Keynote


Ramsey Baghdadi, Prevision Policy (Moderator)

Robert Califf, U.S. FDA

10:35 AM: Session 1 – Interim Overall Survival Evaluations and Implications for Trial Designs and Analysis Plans 


Interim overall survival (OS) data, evaluated alongside early endpoints like progression-free survival and response rate, help assess the risk-benefit profile of new cancer drugs but can be confounded by factors like data maturity and study design features. This session will discuss best practices for trial designs and analysis plans for interim OS analyses in cancer clinical trials as well as the formation of a multistakeholder consortium to conduct simulations, aiming to enhance the accuracy and reliability of interim OS data interpretation. Read the Session 1 White Paper here.


Session 1 Presentation (10 min)


Geoff Oxnard, Eli Lilly and Company

Panel Discussion (40 min) 


Keith Flaherty, Mass General Cancer Center (Moderator)

Nicole Gormley, U.S. FDA

David Mitchell, Patient Advocate

Geoff Oxnard, Eli Lilly and Company

Lisa Rodriguez, U.S. FDA

Antony Sabin, GSK

Audience Q&A (10 min)


11:35 AM: Break


 


11:50 AM: Session 2 – Enhancing Post-Marketing Studies with Pragmatism


Incorporating pragmatic elements into clinical trial designs can enhance the generalizability and efficiency of clinical trials. This session will explore several case studies to inform incorporation of individual pragmatic elements into clinical trials after initial approval to answer specific research questions, enhancing their applicability and efficiency while maintaining regulatory rigor. Read the Session 2 White Paper here.


Session 2 Presentation (10 min)


Paul Kluetz, U.S. FDA

Panel Discussion (40 min) 


Richard Schilsky, University of Chicago (Moderator)

Allen Chen, AstraZeneca

Trixia Camacho, Bristol Myers Squibb

Eva May, Patient Advocate

Neal J. Meropol, Flatiron Health

Peter O’Dwyer, University of Pennsylvania

Donna Rivera, U.S. FDA

Audience Q&A (10 min)


 


12:55 PM: Lunch


 


1:20 PM: Lunch Keynote


Jeff Allen, Friends of Cancer Research (Moderator)

Kimryn Rathmell, National Cancer Institute

1:50 PM: Session 3 – A Common Strategy for Using ctDNA as an Intermediate Endpoint in Prospectively Designed Trials


Friends has collaborated with various stakeholders to support using change in ctDNA levels as an intermediate endpoint in oncology drug development, demonstrating its association with OS. To standardize ctDNA measurement methodologies, this session will discuss an aligned approach for assessing ctDNA changes, focused on using ctDNA in advanced non-small cell lung cancer (NSCLC) treated with immunotherapy. Read the Session 3 White Paper here.


Session 3 Presentation (10 min)


Hillary Andrews, Friends of Cancer Research

Panel Discussion (40 min) 


Charu Aggarwal, Abramson Cancer Center, University of Pennsylvania (Moderator)

Zoe June Assaf, Genentech, A Member of the Roche Group

David Fabrizio, Foundation Medicine, Inc.

Leon Freytor, Johnson & Johnson

Anand Pathak, U.S. FDA

Carol Vallett, Patient Advocate

Paz Vellanki, U.S. FDA

Audience Q&A (10 min)


3:00 PM: Meeting Adjournment


#####

https://milkeninstitute.org/events/future-health-summit-2024


No comments:

Post a Comment

Note: Only a member of this blog may post a comment.